Fol. Biol. 2020, 66, 17-23
https://doi.org/10.14712/fb2020066010017
Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma
References
1. 2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511.
< , A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., Powell, J. I., Yang, L., Marti, G. E., Moore, T., Hudson, J., Jr., Lu, L., Lewis, D. B., Tibshirani, R., Sherlock, G., Chan, W. C., Greiner, T. C., Weisenburger, D. D., Armitage, J. O., Warnke, R., Levy, R., Wilson, W., Grever, M. R., Byrd, J. C., Botstein, D., Brown, P. O., Staudt, L. M. (https://doi.org/10.1038/35000501>
2. 1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89, 3909-3918.
, J. O. (
3. 2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242.
< , B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P., Gisselbrecht, C. (https://doi.org/10.1056/NEJMoa011795>
4. 2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186, 1840-1848.
< , M., Tai, Y. T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., Mutis, T., Bleeker, W. K., Anderson, K. C., Lokhorst, H. M., van de Winkel, J. G., Parren, P. W. (https://doi.org/10.4049/jimmunol.1003032>
5. 2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br. J. Haematol. 146, 171-179.
< , A., Leonard, J. P., Younes, A., Rosenblatt, J. D., Brice, P., Bartlett, N. L., Bosly, A., Pinter-Brown, L., Kennedy, D., Sievers, E. L., Gopal, A. K. (https://doi.org/10.1111/j.1365-2141.2009.07740.x>
6. 2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON- 2): a global, double-blind, randomised, phase 3 trial. Lancet 393, 229-240.
< , S., O’Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illes, A., Tobinai, K., Tsukasaki, K., Yeh, S. P., Shustov, A., Huttmann, A., Savage, K. J., Yuen, S., Iyer, S., Zinzani, P. L., Hua, Z., Little, M., Rao, S., Woolery, J., Manley, T., Trumper, L., Group, E.-S. (https://doi.org/10.1016/S0140-6736(18)32984-2>
7. 2014) Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Lab. Invest. 94, 806-817.
< , M., Soukup, T., Jaksa, R., Molinsky, J., Lateckova, L., Maswabi, B. C., Prukova, D., Brezinova, J., Michalova, K., Vockova, P., Hernandez-Ilizaliturri, F., Kulvait, V., Zivny, J., Vokurka, M., Necas, E., Trneny, M., Klener, P. (https://doi.org/10.1038/labinvest.2014.61>
8. Lemm, E. A., Valle-Argos, B., Smith, L. D., Richter, J., Gebreselassie, Y., Carter, M. J., Karolova, J., Svaton, M., Helman, K., Weston-Bell, N. J., Karydis, L., Williamson, C. T., Lenz, G., Pettigrew, J., Harwig, C., Stevenson, F. K., Cragg, M., Forconi, F., Steele, A. J., Cross, J., Mackenzie, L., Klener, P., Packham, G. (2019) Preclinical evaluation of a novel SHIP1 phosphatase activator for inhibition of PI3K signaling in malignant B-cells. Clin. Cancer Res.
<https://doi.org/10.1158/1078-0432.CCR-19-2202>
9. 2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7, 311-321.
< , M. B., Verploegen, S., Bogels, M., van Egmond, M., Lammerts van Bueren, J. J., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., Parren, P. W. (https://doi.org/10.1080/19420862.2015.1007813>
10. 2016) The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking. J. Immunol. 197, 807-813.
< , M. B., Jansen, J. H., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W., Parren, P. W., Leusen, J. H., Boross, P. (https://doi.org/10.4049/jimmunol.1501351>
11. 2016) Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica 101, 1244-1250.
< , A. M., Diebold, J., Nathwani, B. N., MacLennan, K. A., Muller-Hermelink, H. K., Bast, M., Boilesen, E., Armitage, J. O., Weisenburger, D. D. (https://doi.org/10.3324/haematol.2016.148809>
12. Prukova, D., Andera, L., Nahacka, Z., Karolova, J., Svaton, M., Klanova, M., Havranek, O., Soukup, J., Svobodova, K., Zemanova, Z., Tuskova, D., Pokorna, E., Helman, K., Forsterova, K., Pacheco-Blanco, M., Vockova, P., Berkova, A., Fronkova, E., Trneny, M., Klener, P. (2019) Co-targeting of BCL2 with Venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin. Cancer Res.
<https://doi.org/10.1158/1078-0432.CCR-18-3275>
13. 2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947.
< , A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., Hurt, E. M., Zhao, H., Averett, L., Yang, L., Wilson, W. H., Jaffe, E. S., Simon, R., Klausner, R. D., Powell, J., Duffey, P. L., Longo, D. L., Greiner, T. C., Weisenburger, D. D., Sanger, W. G., Dave, B. J., Lynch, J. C., Vose, J., Armitage, J. O., Montserrat, E., Lopez-Guillermo, A., Grogan, T. M., Miller, T. P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T., Staudt, L. M., Lymphoma/ Leukemia Molecular Profiling Project (https://doi.org/10.1056/NEJMoa012914>
14. 2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198, 851-862.
< , A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., Weisenburger, D. D., Lynch, J. C., Vose, J., Armitage, J. O., Smeland, E. B., Kvaloy, S., Holte, H., Delabie, J., Campo, E., Montserrat, E., Lopez-Guillermo, A., Ott, G., Muller-Hermelink, H. K., Connors, J. M., Braziel, R., Grogan, T. M., Fisher, R. I., Miller, T. P., LeBlanc, M., Chiorazzi, M., Zhao, H., Yang, L., Powell, J., Wilson, W. H., Jaffe, E. S., Simon, R., Klausner, R. D., Staudt, L. M. (https://doi.org/10.1084/jem.20031074>
15. 2019) Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Clin. Lymphoma Myeloma Leuk. 19, 275-284.
< , G., Gopal, A. K., Minnema, M. C., Wakamiya, K., Feng, H., Schecter, J. M., Wang, M. (https://doi.org/10.1016/j.clml.2018.12.013>
16. Vidal-Crespo, A., Matas-Cespedes, A., Rodriguez, V., Rossi, C., Valero, J. G., Serrat, N., Sanjuan Pla, A., Menendez, P., Roue, G., Lopez-Guillermo, A., Gine, E., Campo, E., Colomer, D., Bezombes, C., Lammerts van Bueren, J., Chiu, C., Doshi, P., Perez-Galan, P. (2019) Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica.
<https://doi.org/10.3324/haematol.2018.211904>